- 1次围观
Front Endocrinol (Lausanne). 2025 Dec 10;16:1645593. doi: 10.3389/fendo.2025.1645593. eCollection 2025.
ABSTRACT
OBJECTIVE: Although anti-Müllerian hormone (AMH) is a well-established predictor of oocyte number in assisted reproduction (ART) applications, its potential to reflect embryo quality in ART cycles remains uncertain. This study explored the association between AMH levels and embryo quality, using aneuploidy rates from preimplantation genetic testing for aneuploidy (PGT-A) as an objective indicator of embryo quality.
METHODS: A retrospective analysis was performed on patients (excluding those with male factor infertility) who underwent PGT-A at the Reproduction and Genetics Center of Suzhou Municipal Hospital (2018-2022). Patients were stratified by age (
RESULTS: In 542 PGT-A cycles, AMH levels, euploidy and mosaicism rates negatively correlated with age, while, aneuploidy rates were positively correlated with age. BMI group showed AMH levels shows no significant differences between the groups. However, there were significant differences in euploid, aneuploidy rates among the BMI groups(≥25 kg/m²vs 1.68 ng/mL AMH group had significantly higher euploidy and lower aneuploidy rates. AMH levels negatively correlated with aneuploidy rates.
CONCLUSION: AMH levels serve as a valuable predictor of embryo quality, with the >1.68 ng/mL group showing better quality than the ≤1.68 ng/mL group. AMH levels strongly correlate with female age and the number of biopsy embryos but not BMI. Embryo quality demonstrated a significant decline with increasing female age and a marked improvement with a higher number of biopsy embryos and higher AMH levels. BMI did not linear correlation with embryo quality, thus cannot be considered an independent predictor of embryo quality.
PMID:41450583 | PMC:PMC12727578 | DOI:10.3389/fendo.2025.1645593